128 related articles for article (PubMed ID: 34986961)
1. Time-dependent changes in serum magnesium levels in patients receiving cetuximab with low baseline serum sodium levels.
Yamashiro K; Hirata A; Ota R; Ogata F; Nakamura T; Kawasaki N
Pharmazie; 2021 Dec; 76(12):625-628. PubMed ID: 34986961
[TBL] [Abstract][Full Text] [Related]
2. Identifying optimal magnesium replenishment points based on risk of severe hypomagnesemia in colorectal cancer patients treated with cetuximab or panitumumab.
Kimura M; Usami E; Teramachi H; Yoshimura T
Cancer Chemother Pharmacol; 2020 Sep; 86(3):383-391. PubMed ID: 32789758
[TBL] [Abstract][Full Text] [Related]
3. Risk Factors of Cetuximab-Induced Hypomagnesemia and the Effect of Magnesium Prophylaxis in Patients with Head and Neck Cancer: A Retrospective Study.
Matsukane R; Isshiki R; Suetsugu K; Minami H; Hata K; Matsuo M; Egashira N; Hirota T; Nakagawa T; Ieiri I
Biol Pharm Bull; 2024; 47(3):732-738. PubMed ID: 38556358
[TBL] [Abstract][Full Text] [Related]
4. Clinical relevance and utility of cetuximab-related changes in magnesium and calcium serum levels.
Stintzing S; Fischhaber D; Mook C; Modest DP; Giessen C; Schulz C; Haas M; Boeck S; Michl M; Stemmler J; Laubender RP; Heinemann V
Anticancer Drugs; 2013 Oct; 24(9):969-74. PubMed ID: 23863616
[TBL] [Abstract][Full Text] [Related]
5. [Analysis of Factors Influencing the Development of Hypomagnesemia in Patients Receiving Cetuximab Therapy for Head and Neck Cancer].
Inose R; Takahashi K; Nishikawa T; Nagayama K
Yakugaku Zasshi; 2015; 135(12):1403-7. PubMed ID: 26632157
[TBL] [Abstract][Full Text] [Related]
6. Cetuximab-induced hypomagnesemia in patients with colorectal cancer.
Fakih MG; Wilding G; Lombardo J
Clin Colorectal Cancer; 2006 Jul; 6(2):152-6. PubMed ID: 16945172
[TBL] [Abstract][Full Text] [Related]
7. Importance of magnesium sulfate supplementation in the prevention of hypomagnesemia and hypocalcemia during chemoradiation in head and neck cancer.
Grašič Kuhar C; Strojan P; Zadnik V; Zakotnik B
J Trace Elem Med Biol; 2018 Dec; 50():327-331. PubMed ID: 30262299
[TBL] [Abstract][Full Text] [Related]
8. Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: results from the FIRE-3 (AIO KRK-0306) study.
Schulz C; Heinemann V; Heinrich K; Haas M; Holch JW; Fraccaroli A; Held S; von Einem JC; Modest DP; Fischer von Weikersthal L; Kullmann F; Moehler M; Scheithauer W; Jung A; Stintzing S
Anticancer Drugs; 2020 Sep; 31(8):856-865. PubMed ID: 32639280
[TBL] [Abstract][Full Text] [Related]
9. Increase in cetuximab-induced skin rash and hypomagnesemia in patients receiving concomitant treatment with proton pump inhibitors (PPIs): a possible drug interaction?
Abu-Amna M; Bar-Sela G
Cancer Chemother Pharmacol; 2019 Mar; 83(3):545-550. PubMed ID: 30547192
[TBL] [Abstract][Full Text] [Related]
10. Effect of proton pump inhibitors on the development of hypomagnesemia induced by panitumumab.
Morii Y; Fujimoto S; Nakahara R; Okawa K; Senaha H; Fujiwara K; Tsubaki M; Matzno S; Takegami M; Shimomura K; Nishida S
Pharmazie; 2022 Feb; 77(2):81-84. PubMed ID: 35209968
[TBL] [Abstract][Full Text] [Related]
11. Frequency of hypomagnesemia in hospitalized patients receiving digitalis.
Whang R; Oei TO; Watanabe A
Arch Intern Med; 1985 Apr; 145(4):655-6. PubMed ID: 3985729
[TBL] [Abstract][Full Text] [Related]
12. Predictors of clinical hypomagnesemia. Hypokalemia, hypophosphatemia, hyponatremia, and hypocalcemia.
Whang R; Oei TO; Aikawa JK; Watanabe A; Vannatta J; Fryer A; Markanich M
Arch Intern Med; 1984 Sep; 144(9):1794-6. PubMed ID: 6476998
[TBL] [Abstract][Full Text] [Related]
13. Temporary loss of consciousness during cetuximab treatment of a patient with metastatic colon cancer: a case report.
Fukui T; Suzuki K; Tamaki S; Abe I; Endo Y; Ishikawa H; Kakizawa N; Watanabe F; Saito M; Tsujinaka S; Futsuhara K; Miyakura Y; Noda H; Rikiyama T
Surg Case Rep; 2019 Oct; 5(1):145. PubMed ID: 31637554
[TBL] [Abstract][Full Text] [Related]
14. [Effect of magnesium supplementation on early-stage hypomagnesemia in patients treated with cetuximab].
Demizu M; Ueda H; Osawa M; Chihara S; Igarashi T; Yano K; Kimura F; Tanaka N; Hiratsuka M
Gan To Kagaku Ryoho; 2013 Jul; 40(7):897-900. PubMed ID: 23863731
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the necessity of serum electrolyte monitoring for up to eight weeks after the completion of anti-epidermal growth factor receptor antibody administration.
Pharmazie; 2016 Jul; 71(7):402-407. PubMed ID: 29441917
[TBL] [Abstract][Full Text] [Related]
16. Cetuximab therapy and symptomatic hypomagnesemia.
Schrag D; Chung KY; Flombaum C; Saltz L
J Natl Cancer Inst; 2005 Aug; 97(16):1221-4. PubMed ID: 16106027
[TBL] [Abstract][Full Text] [Related]
17. Refractory hypokalemia caused by cetuximab with advanced colorectal cancer patients: the case series and literature review.
Chen YW; Yang M; Wang MX; Jiang JH; Jiang DY; Chen ZL; Yang L
Anticancer Drugs; 2022 Jan; 33(1):e789-e794. PubMed ID: 34419963
[TBL] [Abstract][Full Text] [Related]
18. Hypomagnesemia and clinical benefits of anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer: a systematic review and meta-analysis.
Hsieh MC; Wu CF; Chen CW; Shi CS; Huang WS; Kuan FC
Sci Rep; 2018 Feb; 8(1):2047. PubMed ID: 29391418
[TBL] [Abstract][Full Text] [Related]
19. Correlations between serum cetuximab and EGFR-related markers, and skin disorders in head and neck cancer patients.
Shibata K; Naito T; Hirakawa S; Suzuki K; Hosokawa S; Mineta H; Kawakami J
Cancer Chemother Pharmacol; 2021 Apr; 87(4):555-565. PubMed ID: 33462734
[TBL] [Abstract][Full Text] [Related]
20. Assessment of frequency and severity of hypomagnesemia in patients with metastatic colorectal cancer treated with cetuximab, with a review of the literature.
Streb J; Püsküllüoğlu M; Glanowska I; Ochenduszko S; Konopka K; Łupkowski R; Michalowska-Kaczmarczyk A; Bochenek-Cibor J; Majka M; Krzemieniecki K
Oncol Lett; 2015 Dec; 10(6):3749-3755. PubMed ID: 26788202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
